|
gptkbp:instanceOf
|
gptkb:chemical_compound
|
|
gptkbp:approvalYear
|
1996
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
L02BG04
|
|
gptkbp:bioavailability
|
99.9%
|
|
gptkbp:boilingPoint
|
Not applicable (decomposes)
|
|
gptkbp:CASNumber
|
gptkb:84371-65-3
|
|
gptkbp:color
|
white to yellowish crystalline powder
|
|
gptkbp:contraindication
|
pregnancy
pre-menopausal women
|
|
gptkbp:developedBy
|
gptkb:Novartis
|
|
gptkbp:drugClass
|
antineoplastic agent
aromatase inhibitor
|
|
gptkbp:eliminationHalfLife
|
2 days
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:hasInChIKey
|
OBLPEUPLXAWFNA-UHFFFAOYSA-N
|
|
gptkbp:hasMolecularFormula
|
C17H11N5
|
|
gptkbp:hasSMILES
|
N#Cc1ccc(cc1)C=n2ncnc2c3ccc(cc3)C#N
|
|
gptkbp:hasUNII
|
T6X3OCM3ZU
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
84371-65-3
|
|
gptkbp:IUPACName
|
gptkb:4,4'-(1H-1,2,4-Triazol-1-ylmethylene)dibenzonitrile
|
|
gptkbp:legalStatus
|
expired
prescription only
|
|
gptkbp:marketedAs
|
gptkb:Femara
|
|
gptkbp:mechanismOfAction
|
aromatase inhibitor
|
|
gptkbp:meltingPoint
|
184-185°C
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
285.31 g/mol
|
|
gptkbp:name
|
gptkb:Letrozole
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:PubChem_CID
|
3902
CHEMBL716
DB01006
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gptkb:bone
nausea
fatigue
joint pain
hot flashes
|
|
gptkbp:solubility
|
slightly soluble
|
|
gptkbp:usedFor
|
treatment of breast cancer
|
|
gptkbp:bfsParent
|
gptkb:Mifepristone
|
|
gptkbp:bfsLayer
|
7
|